LONDON, August 29, 2013 /PRNewswire/ --
On Wednesday, August 28, 2013, all three benchmark indexes of the US equity market closed higher, with the Dow Jones Industrial Average gaining 0.33%, the S&P 500 gaining 0.27%, and the NASDAQ Composite Index advancing 0.41%. Shares in the healthcare sector ended on a mixed note, even as the broader market edged higher. The major movers included Johnson & Johnson (NYSE: JNJ), Mylan Inc. (NASDAQ: MYL), Brookdale Senior Living Inc. (NYSE: BKD), and Array BioPharma Inc. (NASDAQ: ARRY). AAAResearchReports.com initiated preliminary technical research on JNJ, MYL, BKD, and ARRY. These free reports are accessible by signing today at:
Shares in Johnson & Johnson gained 0.42% on Wednesday, reversing some of their recent losses. The company's shares fluctuated between $85.88 and $86.91, before finishing the day at $86.53. A total of 7.42 million shares were traded, which is below the daily average volume of 9.76 million. Johnson & Johnson's shares have lost 1.23% in the last three trading months, outperforming the S&P 500 which has lost 1.51%% during the same period. Moreover, the stock is now trading above its 200-day moving average. The free technical analysis on JNJ is available by signing up at:
Mylan Inc.'s shares ended higher on Wednesday, tracking gains in the broader market. The company's shares vacillated between $34.59 and $35.24 before finishing the day 0.86% higher at $35.06. A total of 2.43 million shares were traded, which is below the daily average volume of 4.17 million. The company's shares have gained 4.88% in the last one month and 10.84% in the last three months, outperforming the S&P 500 which has lost 3.35% and 1.51% during the respective periods. Further, Mylan Inc.'s stock is trading above its 50-day and 200-day moving averages. Register now to download free research on MYL at:
Shares in Brookdale Senior Living Inc. posted modest gains on Wednesday, ending the day at $25.52, up 0.16% from the previous day's price of $25.48. The company's shares fluctuated between $25.45 and $25.73. A total of 0.69 million shares were traded, which is below the daily average volume of 1.11 million. The company's shares have lost 2.22% in the last three trading sessions, compared to a loss of 1.72% in the S&P 500 during the same period. Moreover, the stock is trading below its 50-day and 200-day moving averages. A free report on BKD can be accessed by registering at:
Array BioPharma Inc.'s stock fell sharply on Wednesday, extending the losses from previous trading sessions. The company's shares fluctuated between $5.52 and $5.80 before closing the day at $5.66, down 1.91% from the previous day's closing price of $5.77. A total of 1.44 million shares were traded, which is below the daily average volume 1.85 million. The company's shares have fallen by 5.98% in the previous three trading sessions and 11.01% in the last one month. Despite the recent losses, the stock is currently trading above its 200-day moving average. Register with AAA Research Reports and download research on ARRY for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE AAA Research Reports